Life-Threatening Myositis in a Patient With EGFR-Mutated NSCLC on Osimertinib: Case Report
{{output}}
Osimertinib is the standard of care for the first-line treatment of EGFR-mutated NSCLC. We report a case of a 52-year-old woman who developed life-threatening myopathy because of treatment with osimertinib. Limited instances of myositis have been previously re... ...
